PsychedelicNewsBreaks

TuesdayFeb 07, 2023 1:52 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar and chronic pain,” a recent article reads. “In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a…

Continue Reading

TuesdayFeb 07, 2023 12:12 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward with its proposed phase 1 clinical trial in Canada. The notification came in the form of a No Objection Letter (“NOL”) from Health Canada. The letter gives FSD Pharma regulatory approval to proceed with its clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of multiple sclerosis. The first-in-human clinical trial is designed to evaluate the safety…

Continue Reading

ThursdayFeb 02, 2023 11:34 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent’s allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress disorder (“PTSD”). With the patent, the company expands its intellectual property and technology rights for the treatment of rare diseases. “After a comprehensive review by USPTO, we are pleased with the scope of the granted…

Continue Reading

WednesdayFeb 01, 2023 11:15 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being conducted at the Centre for Human Drug Research in the Netherlands; it is the largest-ever Phase 1 DMT trial conducted to date. Based on previous studies, CYB004 has shown potential to deliver an improved bioavailability…

Continue Reading

TuesdayJan 31, 2023 11:19 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has announced a stock repurchase program. According to the company, its board of directors has approved the program, which will acquire up to $1 million of the company's common stock. The announcement noted that the company could purchase common stock in a variety of ways, including in the open market and through privately negotiated transactions; all transactions will be in compliance with United States Securities and Exchange Commission rules and guidelines. The repurchase of stocks will depend on available liquidity, cash flows and market conditions…

Continue Reading

MondayJan 30, 2023 11:00 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS (“MCAD”) at two clinical sites in the USA, with a Canadian site to be ready to recruit soon. “FSD201 is a unique proprietary formulation of palmitoyl ethanolamide, and already received the new molecular entity (‘NME’) designation for a potential 505(b)(1) application to the U.S. FDA. This…

Continue Reading

ThursdayJan 26, 2023 11:47 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for the treatment of major depressive disorder, and CYB004, which is being evaluated for the treatment of generalized anxiety disorder. According to the announcement, the event will feature an interim readout from CYBN’s ongoing phase 1/2a…

Continue Reading

FridayJan 20, 2023 12:09 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Eying Broad Market Opportunities for Its Liposomal Joint Homing Peptide

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently revealed positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. “Silo Pharma provided an update on the ongoing study as of Dec. 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (“DEX”), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the…

Continue Reading

ThursdayJan 19, 2023 11:22 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pharma’s recent submission of its clinical trial application for an upcoming phase a trial evaluating Lucid-MS. A candidate for treatment of multiple sclerosis (“MS”), Lucid-MS is a first-in-class neuroprotective compound featuring a novel mechanism action that has been shown to prevent myelin degradation, or demyelination, a significant cause of MS and other neurodegenerative diseases. According to the announcement, Lucid-MS…

Continue Reading

WednesdayJan 18, 2023 10:35 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics. The possibility of using this technology to develop a predictive tool to aid…

Continue Reading